Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data indicate ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

Credit: Celltrion Avtozma, formerly known as CT-P47, is an interleukin-6 receptor antagonist. Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be ...

Findings showed tocilizumab-anoh had comparable efficacy, pharmacokinetics, safety, and immunogenicity with Actemra. The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a ...